Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

I hear you on the Rett PR debacle but the bigger issue to me is that there is a pattern of similar instances where Missling shoots himself in the foot and damages shareholder value in the process. It seems clear that no lessons have ever been learned and Missling is uninterested in doing anything differently.

The tragedy of Anavex is that based on early data A 2-73 looks like it has real potential. However, the broader biotech investor community overlooks the science because the company’s reputation is so checkered. Once investors are reasonably comfortable with the science, what they’re investing in is management. Good science is not worth much if you have doubts about whether management has the competence and experience to give investors confidence. I believe the broader biotech investment community (and the healthcare media) have their doubts. It’s why I believe Anavex shareholders would be best served by bringing in a seasoned CEO and management team (and some remaking of the BOD) that investors can have confidence in.